NASDAQ · EXAI
Exscientia plc
$4.84$0.00 (0.0%)
Exscientia plc: Healthcare · Biotechnology.
Loading market information…
NASDAQ · ACCD · USD
Stock price, earnings
Quote as of Apr 8, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Accolade, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.4% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Accolade, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Accolade, Inc., along with its subsidiaries, specializes in providing innovative, technology-driven solutions across the United States. These solutions are designed to empower individuals to better understand, navigate, and ultimately leverage both the complex healthcare system and their available workplace benefits. At the core of its offering is a robust cloud-based platform that delivers comprehensive, multimodal support. This assistance comes from a dedicated team of health assistants and clinical professionals, including registered nurses, physician medical directors, and specialists in behavioral health. Furthermore, Accolade extends its services to include valuable second opinion consultations and crucial decision-making support for healthcare matters. The company primarily serves employers who aim to furnish their employees and their families with a unified, easily accessible resource for all their health, medical care, and benefits-related inquiries. Established in 2007, Accolade, Inc. maintains its corporate headquarters in Plymouth Meeting, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:26 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2024 | Oct 4, 2023 | -$0.43+23.21% vs estimate | $96.86M+2.95% vs estimate |
|---|
| Q1 2024 | Jun 29, 2023 | -$0.52+18.75% vs estimate | $93.23M-0.94% vs estimate |
|---|
THE ANALYST VIEW
20 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$4.84$0.00 (0.0%)
Exscientia plc: Healthcare · Biotechnology.
$10.00$0.00 (0.0%)
Apollo Endosurgery, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.91% below the high.
$5.59-$0.01 (-0.09%)
BioDelivery Sciences International, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.53% below the high.
$8.16$0.00 (0.0%)
Regulus Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.22% below the high.
$8.68$0.00 (0.0%)
Sage Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 7.26% below the high.
$1.43-$0.01 (-0.35%)
Sharecare, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.69% below the high.
$23.90-$0.10 (-0.42%)
Claritev Corporation’s quoted price sits in the lower half of its reported 52-week range, 67.56% below the high.
$2.10-$0.10 (-4.55%)
SomaLogic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.59% below the high.
